Calypso and Elekta combine for radiation therapy pact
This article was originally published in Clinica
Executive Summary
Calypso Medical Technologies is to integrate its tumour tracking system into Elekta’s radiotherapy technology. The two firms have entered a development agreement which will see them jointly produce technology designed to treat prostate cancer, as well as other cancers that are difficult to treat with radiation targets such as pancreas and lung. The Calypso System is the only commercially-available real-time tumour tracking device, while Elekta’s Synergy and Precise linear accelerators deliver intensity-modulated radiotherapy. Financial terms of the collaboration were not disclosed.